[HTML][HTML] … of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation …
H Kim, YS Lee, TH Kim, MJ Cha, JM Lee… - The Korean Journal …, 2020 - ncbi.nlm.nih.gov
… high early discontinuation rate of vitamin K antagonists (VKAs) is a … persistence in real-world
practice after the approval of NOACs, … This study showed that nonpersistence to apixaban or …
practice after the approval of NOACs, … This study showed that nonpersistence to apixaban or …
Efficacy and safety of antithrombotic therapy with non-vitamin K antagonist oral anticoagulants after transcatheter aortic valve replacement: a systematic review and …
Q An, S Su, Y Tu, L Gao, G Xian, Y Bai… - Therapeutic …, 2021 - journals.sagepub.com
… In patients with atrial fibrillation (AF) and other indications for … ), vitamin K antagonists (VKAs)
therapy with a continuation of … therapy in terms of safety outcome (bleeding), and apixaban …
therapy with a continuation of … therapy in terms of safety outcome (bleeding), and apixaban …
The importance of appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation
J Beyer-Westendorf, M Fay, W Amara - TH Open, 2021 - thieme-connect.com
… usually prescribed to patients with AF in clinical practice. … , including vitamin K antagonists
(VKAs), such as warfarin, … For apixaban-treated patients, under-dosing was associated with an …
(VKAs), such as warfarin, … For apixaban-treated patients, under-dosing was associated with an …
Systematic review and meta-analysis of randomized controlled trials on safety and effectiveness of oral anticoagulants for atrial fibrillation in older people
G Erdem, M Esme, BB Doğu - Irish Journal of Medical Science (1971-), 2022 - Springer
… , as most commonly used vitamin K antagonists (VKAs), was done … patients aged 80 years
and older, utilization of apixaban was … is as it is used in routine clinical practice in Japan. It was …
and older, utilization of apixaban was … is as it is used in routine clinical practice in Japan. It was …
Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany
…, A Cuneo, R Bekeredjian, O Ritter, B Hailer, K Hertting… - Herz, 2023 - Springer
… triple antithrombotic therapy (TAT) with a vitamin K antagonist (… clinical practice, planned
duration of combination therapies … therapy (n = 425) consisted of rivaroxaban in 195, apixaban …
duration of combination therapies … therapy (n = 425) consisted of rivaroxaban in 195, apixaban …
[HTML][HTML] Adherence to direct oral anticoagulants in patients with non-valvular atrial fibrillation: A cross-national comparison in Six European Countries (2008–2015)
M Sabaté, X Vidal, E Ballarin, S Schmiedl… - Frontiers in …, 2021 - frontiersin.org
… of efficacy study results to clinical practice, as efficacy might … Apixaban is the DOAC with the
highest persistence rate and … all databases except in the German AOK and Dutch Mondriaan …
highest persistence rate and … all databases except in the German AOK and Dutch Mondriaan …
(Absence of) Association Between Non–Vitamin K Antagonist Oral Anticoagulant Therapy and Urinary Tract Infection in Patients With Atrial Fibrillation
J Heidemann, C Tanislav, K Kostev - Journal of Cardiovascular …, 2021 - journals.lww.com
… in general practices in Germany. This study contains patients diagnosed with atrial fibrillation
who … rivaroxaban, apixaban, dabigatran, and edoxaban compared with therapy with …
who … rivaroxaban, apixaban, dabigatran, and edoxaban compared with therapy with …
[PDF][PDF] … EFFECTIVENESS AND SAFETY OF DIRECT ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
S Suwatcharangkoon - rama.mahidol.ac.th
… Vitamin K antagonist (VKA) such as warfarin inhibits vitamin … in clinical practice and monitor
the postmarket drug safety. In a … conducted for comparing efficacy and safety between each …
the postmarket drug safety. In a … conducted for comparing efficacy and safety between each …
Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study
… on and off therapy for standard and low-dose DOACs (apixaban, … (OAC) including the vitamin-K
antagonist, warfarin and the … disparities in DOAC dosing practice and recommendations, …
antagonist, warfarin and the … disparities in DOAC dosing practice and recommendations, …
[HTML][HTML] A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation
RD Lopes, SE Berger, M Di Fusco, A Kang… - International Journal of …, 2020 - Elsevier
… or vitamin K antagonists. HTA methods and information on … practice, likely due to its
established familiarity and lower … (Germany [50], France [35], and the Netherlands [apixaban and …
established familiarity and lower … (Germany [50], France [35], and the Netherlands [apixaban and …